#1CRONOS GROUP INVESTOR PRESENTATION March 13, 2024 NASDAQ / TSX TICKER CRON#2DISCLAIMERS & CAUTIONARY STATEMENTS CRONOS GROUP INC. This document may contain forward-looking information or forward-looking statements within the meaning of applicable U.S. and Canadian securities laws and court decisions (collectively, "forward-looking information"). All information contained in this communication that is not clearly historical in nature or that necessarily depends on future or subsequent events is forward-looking information prepared as of the date hereof and is based upon the opinions and estimates of management and the information available to management as of the date hereof. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussion of strategy. Forward-looking information is based upon a number of current internal expectations, estimates, projections, assumptions and beliefs that, while considered reasonable by management, are inherently subject to significant business, economic, competitive and other uncertainties and contingencies. Forward-looking information is not a guarantee of future performance and involves. known and unknown risks, uncertainties and other factors (including the risk factors disclosed under the heading "Risk Factors" in the Company's most recent annual, quarterly or other reports filed with the U.S. Securities and Exchange Commission (the "SEC"), which are available under the Company's EDGAR profile at www.sec.gov/edgar, and applicable securities regulatory authorities in Canada on the Company's SEDAR profile at www.sedar.com), that may cause actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking information. Any estimates, investment strategies or views expressed in this document are based upon current market conditions, and/or data and information provided by unaffiliated third parties, and are subject to change without notice. To the extent any information in this document was obtained from third party sources, the Company has not independently verified that information, and there is a risk that the assumptions made and conclusions drawn by the Company based on such information are not accurate. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on this forward-looking information. This presentation includes Adjusted EBITDA, a non-GAAP financial measure, which excludes non-cash items and items that do not reflect management's assessment of ongoing business performance. Management defines Adjusted EBITDA as net income (loss) before interest, tax expense (benefit), depreciation and amortization adjusted for: share of income (loss) from equity method investments; impairment loss on goodwill and intangible assets; impairment loss on long-lived assets; (gain) loss on revaluation of derivative liabilities; (gain) loss on revaluation of financial instruments; transaction costs related to strategic projects; impairment loss on other investments; foreign currency transaction loss; other, net; loss from discontinued operations; restructuring costs; inventory write-downs resulting from restructuring actions; share-based compensation; and financial statement review costs (and reserves) related to the restatements of the Company's 2019 and 2021 interim financial statements, including the costs related to the settlement of the Securities and Exchange Commission's and the Ontario Securities Commission's investigations of the restatements and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement. Management believes that Adjusted EBITDA provides the most useful insight into underlying business trends and results and provides a more meaningful comparison of period-over-period results. Management uses Adjusted EBITDA for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. Non-GAAP measures should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. A reconciliation of Adjusted EBITDA to net income (loss) has been included in this presentation. 2#3AGENDA I. Mission and Strategy II. Brand Portfolio III. Global Supply Chain and Distribution IV. Financial Summary V. Management Team and Board of Directors#4THE CRONOS MINDSET MISSION Improve people's lives by unlocking the full potential of cannabis. PURPOSE We aspire to be the leading cannabinoid company with brands that connect consumers, a winning culture, and industry leading innovation. VALUES People & Community We believe in fostering the most valuable global cannabis community comprised of passionate and daring people. Quality Products We believe in developing innovative and meaningful products that meet the needs and exceed the expectations of our customers. Integrity & Leadership We take pride in leading the industry forward responsibly. 4#5BRAND PORTFOLIO#6CRONOS GROUP BUILDING A PORTFOLIO OF BRANDS Spinach до PEACENATURALS® MEDICINAL CANNABIS LORD JONES BRAND POSITIONING Mainstream Wellness Premium PRODUCT OFFERING(1) Dried Cannabis, Pre-Rolls, Vaporizers, Edibles Dried Cannabis, Cannabis Tinctures, Pre-rolls Pre-Rolls, Vaporizers, Edibles GEOGRAPHIC AVAILABILITY (1) Not all product formats are available in all markets Canada Canada, Israel and Germany Canada CO 6#7E LORD JONES LORD JONES | BRAND IDENTITY REIMAGINED | LEGACY REFRESHED LORD JONES Ⓡ LORD JONES PURE ORD NES RE ON#8Spinach Mainstream Adult-use Friends. Fun. Legendary Cannabis. Three things that make our world go round, and round. Each better together, always and forever. SpinachⓇ products are here for all the fun that only happens with friends. Where we grow closer by the experiences we share, and the moments made a little more epic whenever there's legendary cannabis to go around. * THC Spinach GMO Cookies Indica SOURZ BY Spinach PEACH ORANGE WARNING: The smoke from cannabis is harmful. Toxic and carcinogenic chemicals found in tobacco smoke such as polyaromatic hydrocarbons, aromatic amines, and N-heterocyclics are also found in cannabis smoke. MISE EN GARDE : La fumée de cannabis est nocive. Les produits chimiques toxiques et cancer genes, comme les hydrocarbures aromatiques polycycliques, les amines aromatiques et les N hétérocycliques, présents dans la fumée du tabac sont également présents dans la fumée du cannabis Health Canada/Sance Canada 1 pre-rolled joint/1 joint préroulé Blue Dream Sativa THC Spinach HYBRID 10MG THC/10MG CBD H SOURZ BY Spinach BLUE RASPBERRY WATERMELON DICA THC/PACK STRAWBERRY MANGO SATIVA 10MG THC/PACK DANCEHAL THC Spinach Spinach Feelz THC + CBG Soing THC +> CBG = CHILL BLISS Tropical Diesel APPY CBG RELAXED HIGH 7:1 THC: CBG E CARTRIDGE Spinach™ Dancehall Sativa N-heterocyclics are also found in cannabis smoke. WARNING: The smoke from cannabis is harmful. Toxic and carcinogenic chemicals found in tobacco smoke such as polyaromatic hydrocarbons, aromatic amines, and MISE EN GARDE : La fumée de cannabis est nocive. hydrocarbures aromatiques polycycliques, les amines Health Canada/Santé Canade Les produits chimiques toxiques et cancérigènes, comme les aromatiques et les N hétérocycliques, présents dans la fumée du tabac, sont également présents dans la fumée du cannabis. 3 pre-rolled joints/3 joints préroulés Spinac#9CLEAR NEW & UPLIFT HÄH KING MANGO KIWI HAZE CBC Spinach MANGO LIME Spinac Feelz TM THE+CBC FEELZ. THE WAY YOU WANT Introducing another friend to our Spinach FEELZ™ line-up#10PEACENATURALS® MEDICINAL CANNABIS Wellness Accessible high-quality cannabis for medicinal purposes. CRONES go PEACENATURALS MEDICINAL LAMAN GMO CT20/C4 GMO (0.16 0.24) 2 01 0.0258 25'C ייל וד נעים ג'י אם או T20/C4 חת קנביס רפואי אינדיקה INDICA / 10 גרם דרך המתו: שאיפה )יישו/אידוי תפרחת / גליליות / שמן PEACENATURALS MEDICINAL CANNABIS שמן קנס תואר שמן קנביס רפואי T10/C10 נועם מנטה עדינה לפחות דליליות /שמן - - PEACENATURALS T10/C10 013 10 Medica IMC-Medical Gra ם מסוכן CONTROLLED SUB PEACENATURALS Wedding Cake T20/C4 תפרחת / גליליות / שמן CRONCS PEACENATURALS MEDICINAL CANNANIS קוסרא שמן קנביס רפואי T20/C4 בטעם לימון ופירות יער ת / כלת / שמן X PEACENATURALS 120/04 go THOO 07310 Medic IMC-Medical G 16-024 שון איתם על Wedding Cake וודינג קייק T20/C4 תפרחת קנביס רפואי היברידי/ HYBRID/10 גרם דרך המתן: שאיפה (עישון/אידוי) Space CK ספיים מי קיי T20/C4 שם הזן = SPACE CAME ת קנביס רפואי היברידי /HYBRID /15 גרם דרך החתן: שגיסה (עישון/אידוי) go Sonic Fuel סוניק פיול 383 Space CK T20/C4 שם הזן = SPACE CANE תפרחת/גליליות / שמן Sonic Fuel C T20/C4 T20/C4 SONIC LEMON FUEL 17.00 חמ תתקנביס רפואי ירידי/HYBRID/ 10 גרם דרך המחן: שאינה עישון/אידוי) SONIC LEMON FULL תפרחת /גליליות / שמן pito CONTROLLED CONTROLLE#11GLOBAL SUPPLY CHAIN AND DISTRIBUTION#12JV Structure and Licenses Strategic JV with Kibbutz Gan Shmuel, a commercial kibbutz and food company. CRONOS ISRAEL Israel Market Israel is a leader in research and development on medical cannabis. Cronos' revenue within Israel was $21.1 million in 2023. Cronos Group Ownership Interest Subsidiaries Cronos Israel G.S. Cultivation Ltd. 70% CRONOS ISRAEL Currently in market with PEACE NATURALS® and LITTM branded cannabis products. Cronos Israel G.S. Manufacturing Ltd. 90% 90% Cronos Israel G.S. Store Ltd. Cronos Israel G.S. Pharmacy Ltd. 90% The Company has the necessary regulatory approvals to produce, manufacture and sell dried cannabis flower, pre-rolls and oil products. Facility Ideal climate enables efficient production of high-quality cannabis. Over 1,000 agriculturally skilled Kibbutz members live on site and existing infrastructure available to support operations. Gan Shmuel currently exports to 35 countries across Europe and Asia through Gan Shmuel Foods Ltd., a publicly traded food company listed on the Tel Aviv Exchange. CRONOS THICK T15/C3 THCOTE PEACENATURALS go גיי אט קוס GS KUSH Additional Partnerships: Cannasoul Analytics In April 2020, Cronos Israel entered into a collaboration agreement with Cannasoul Analytics Ltd. ("Cannasoul"), a cannabis research company dedicated to developing scientific intellectual property, medical products, and technologies, to develop a commercial cannabis analytical testing laboratory onsite at Cronos Israel. Cannasoul intends to operate the laboratory and conduct in-house commercial analytical testing for Cronos Israel and third-party clients. CANNASOUL Analytics 12#13JV STRUCTURE 50/50 joint venture between Cronos and a group of investors led by Bert Mucci, principal of al Canadian large-scale greenhouse operator, Mucci Farms. COMMERCIAL BUSINESS In 2023, Cronos Grow Co reported to the Company preliminary. unaudited net revenue of approximately $19.6 million to licensed producers excluding sales to Cronos. Cronos intends to leverage Grow Co's capabilities in premium flower cultivation and efficient downstream processing, with the aim to improve profitability of the Company's Canadian operations. CRONOS GROWCO (CANADA) Joint Venture With Best-In-Class Agricultural Operator GROWCO GROWCO GROWCO GROWCO OS OWCO CRONOS GROW 13#14PRIMARY COUNTRIES OF DISTRIBUTION Canadian Adult-use Cannabis Spinach LORD® JONES Cronos Israel Gan Shmuel, Israel Israeli Medical Cannabis до PEACENATURALS® MEDICINAL CANNABIS Lit Cronos Israel distributes branded cannabis products to the Israeli medical cannabis market through pharmacies. Medical cannabis patients must obtain licenses either directly from physicians who have been authorized to grant patient licenses or from the Yakar following a request from the patient's physician to purchase and consume medical cannabis. Cronos Fermentation* Winnipeg, Manitoba Peace Naturals* Stayner, Ontario Cronos GrowCo Kingsville, Ontario Cronos Group HQ Toronto, Ontario ADULT-USE - 3 Retail Models Within This Channel 1 FULL CROWN CORPORATION: - Procurement is led by Crown Corp and the retail outlets online retail stores are operated by Crown Corp 2 HYBRID CROWN / PRIVATE: - Procurement is led by Crown Corp and the online retail store is operated by the Crown Corp Brick-and-mortar retail outlets can be both Crown Corp and / or privately owned and operated 3 FULL PRIVATE: - The procurement, retail outlets and online retail are privately owned and operated Germany and Australia Medical Cannabis cansativaⓇ до GROUP PEACENATURALS® MEDICINAL CANNABIS Cansativa is a leading medical cannabis distributor and has a network of approximately 2,000 high-volume, cannabis- focused, pharmacies domestically. VITURA Cronos supplies Vitura's house brand with cannabis flower. *On November 26, 2023, the Company entered into an agreement for the sale and leaseback for its Peace Naturals facility. In addition, on August 4, 2023 the Board approved plans to wind-down operations at Cronos Fermentation and list the facility for sale. For more information on both transactions please refer to our latest Form 10-K for the period ended December 31, 2023. 14#15wwwww FINANCIAL SUMMARY#16FINANCIAL OVERVIEW (in thousands of USD) Three Months Ended December 31. Change Year ended December 31. Change 2023 2022 S % 2023 2022 S % Consolidated net revenue $ 23,915 $ 22,033 $ 1,882 9 % $ 87,241 $ 86,749 00 S 492 1 % Cost of sales 21,913 20,773 1,140 5 % Inventory write-down 89 89 N/A 74,527 805 Gross profit $ 1,913 $ 1,260 $ 653 52 % $ 11,909 $ 15,436 09 Gross margin 8 % 6% N/A 2 PP 14 % 18 % 71,313 3.214 5 % 805 (3,527) N/A (23)% N/A (4)pp Net income (loss)() $(45,151) $(76,181) $ 31,030 41 % $ (70,439) $(155,178) S 84,739 55 % Adjusted EBITDA (ii) $(14,790) $(19,018) $ 4,228 22% $(61,564) (70,291) 8,727 12 % Other Data Cash and cash equivalents(iv) Short-term investments(iv) $669,291 $764,644 $ (95,353) 192.237 113,077 79,160 (12)% 70 % 1,792 768 1,024 133 % 3,423 Capital expenditures(V) (i) Gross margin is defined as gross profit divided by net revenue. 5,032 (1,609) (32)% (ii) The improvement year-over-year in quarterly net income (loss) was primarily driven by lower income tax expense, an improvement in operating loss and higher interest income. (W) See "Non-GAAP Measures" for more information, including a reconciliation of adjusted earnings (loss) before interest, taxes, depreciation and amortization ("Adjusted EBITDA") to net income (loss). (iv) Dollar amounts are as of the last day of the period indicated. (v) Capital expenditures represent component information of investing activities and is defined as the sum of purchase of property, plant and equipment, and purchase of intangible assets. For more details on the Company's Adjusted EBITDA calculation, including reconciliations to net income (loss), please go to page 24 of this presentation. 16#17Overall, Spinach is the #2 (1) cannabis brand Spinach WE HAVE SIGNIFICANT UNDERAPPRECIATED VALUE $862 million in cash and cash equivalents and zero debt (2) Our Canadian business reached $64.7 million in revenue in 2023 (2) In edibles, the #1 (1) brand In flower, the #1 (1) brand In pre-rolls, the #8 (1) brand and quickly taking share In vape, the #3 (1) brand, and also gaining ground. We have a leading brand in Israel, totalling revenue of $21.1 million in 2023 (2) We have an approximate 5.9% stake in PharmaCann, one of the largest private U.S. MSOs. Our stake is currently on our books for $25.7 million. (2) PHARMACANN Additional Investments/Assets / Partnerships We have an approximate 10% stake in Vitura, a leading publicly-traded Australian medical cannabis provider, worth approximately $9.6 million. as of Q4 2023. (2) VITURA We own 50% of the equity in Cronos Grow Co, which is profitable. We ended the quarter with a remaining balance of approximately $83 million on our combined loans to Grow Co and its partners. (2) CRONOS GROWCO We have a growing portfolio of proprietary fermentation methods, product formulations and genetics. Spinac до PEACENATURALS MEDICINAL CANNABIS We have an exclusive partnership with Altria on a global basis. Altria SOURCE: (1) Hifyre data for the month of December 2023, (2) Cronos public filings 17#18STRATEGIC INVESTMENT IN PHARMACANN, A LEADING U.S. CANNABIS COMPANY Investment is Expected to Position Cronos Group to Benefit from Rapid Growth in the U.S. Cannabis Market CRONOS GROUP PHARMACANN Investment Overview and Strategic Rationale On June 14, 2021, Cronos Group announced a strategic investment in PharmaCann. A wholly-owned subsidiary of Cronos Group purchased an option to acquire an approximately 10.5% ownership stake in PharmaCann on a fully-diluted basis for a total consideration of approximately $110.4 million. Following the exercise of the option (which will be based upon various factors, including the status of U.S. federal cannabis legalization), Cronos Group and PharmaCann will enter into commercial agreements that would permit each party to offer its products through either party's distribution channels. On February 28, 2022, PharmaCann completed the acquisition of LivWell Holdings, Inc. ("LivWell"). As of December 31, 2023, the Company's ownership percentage in PharmaCann on a fully diluted basis was approximately 5.9%. Source: PharmaCann Website, Cronos Group Filings WA PharmaCann's Geographic Footprint VT ME MT ND OR MN ID SD WI NY MA WY MI CT RI IA PA NJ NE NV OH DE UT IL IN CO WV MD CA KS VA MO KY DC NC TN OK AZ NM AR SC MS AL GA TX LA FL PharmaCann has a broad geographic footprint in the U.S. and has built an efficient, effective and scalable operating model across the following eight states: New York, Illinois, Ohio, Maryland, Pennsylvania, Michigan, Colorado and Massachusetts. 18#19STRATEGIC INVESTMENT In March 2019, Altria Invested $1.8B for a 45% Stake in Cronos Group Common Equity Proven expertise in brand and product development in highly regulated markets Financial capacity and wherewithal to support growth plan and capitalize. on emerging market opportunities Leading technology and R&D capabilities Leading global cannabis producer Altria CRONOS GROUP Unique R&D and production capabilities Talented management team, with a track-record of success Partnership accelerates Cronos Group's execution and achievement of strategic objectives 19#20MANAGEMENT TEAM & BOARD OF DIRECTORS#21MANAGEMENT TEAM Our management team comprises experts in their fields, with a goal to establish the most valuable international cannabis company. They are passionate, daring people, driven by quality and integrity, who are determined to write history, not read about it. MIKE GORENSTEIN Chairman, President and Chief Executive Officer JEFF JACOBSON Chief Growth Officer SHANNON BUGGY SVP, Global Head of People JAMES HOLM Chief Financial Officer ANNA SHLIMAK SVP, Corporate Affairs and Strategy TERRY DOUCET General Counsel and Corporate Secretary ARYE WEIGENSBERG SVP, Head of Research and Development RAN GORELIK General Manager, Cronos Israel, Cronos Group's strategic joint venture with Kibbutz Gan Shmuel 21#22BOARD OF DIRECTORS 2234 MIKE GORENSTEIN Chairman, President and Chief Executive Officer Mike serves as Cronos Group's Chairman, President and Chief Executive Officer. In addition, Mike is a Co- founder and passive Member of Gotham Green Partners. Before joining the Company, Mike was the Vice President and General Counsel at Alphabet Partners, LP, a New York based investment management firm. Prior to Alphabet Partners, LP, he was a corporate attorney at Sullivan & Cromwell LLP. JIM RUDYK Lead Director, Audit Committee Chair, Compensation Committee Jim is the Chief Financial Officer of Ag Growth International Inc. ("AGI") where he is responsible for finance, accounting, business intelligence and information technology. Jim is a seasoned executive with more than 25 years of financial and operational experience, and a track record of supporting. ambitious growth plans. Prior to joining AGI, Jim served as the CFO of Sofina Foods Inc. from Sept. 2019 until May 2020 and was the CFO of Roots Corporation from 2016 through Aug. 2019, where he helped the company grow and transition from a family- led organization to a Canadian public company. KAMRAN KHAN Kamran Khan serves as Vice-President and Associate General Counsel with Altria Client Services Inc. Over the last 16 years, Kamran has managed a wide portfolio of litigation, business counseling and regulatory matters supporting Altria's family of companies. In his current role, Mr. Khan leads a team responsible for supporting Government Affairs, Corporate Citizenship, Regulatory Affairs, and Privacy. Previously, Mr. Khan led a team providing legal support for all aspects of the development, marketing, and sale of innovative tobacco products. JASON ADLER Audit Committee, Compensation Committee Chair Jason is a Co-founder and Managing Member of Gotham Green Partners, a private equity firm focused primarily on early-stage investing in companies in the cannabis industry. Prior to co-founding Gotham Green, Jason was the Co- founder and CEO of Alphabet Partners, LP. Jason also founded Geronimo, LLC, a broker- dealer and member of the American Stock Exchange. KENDRICK F. ASHTON, Jr. Audit Committee DOMINIK MEIER ELIZABETH SEEGAR Compensation Committee Kendrick is the Co-founder and Co-Chief Executive Officer of The St. James, a leading developer and operator of performance, wellness and lifestyle brands, experiences and destinations. Prior to founding The St. James, Kendrick was a founding member and Managing Director of Perella Weinberg Partners, a boutique financial services firm. Before joining Perella Weinberg, he was an investment banker at Goldman, Sachs & Co. and gained legal experience at Cravath, Swaine & Moore and Wachtell, Lipton, Rosen & Katz. Dominik Meier serves as the Vice President of Consumer & Marketplace Insights & Innovation for Altria Client Services. Before assuming his current role, Mr. Meier served as Vice President of Strategy, Consumer & Marketplace Insights for Altria Ventures Inc. Since joining the Altria family of companies in 2005, Mr. Meier has served in a variety of roles including as the General Manager and Managing Director of Nat Sherman LLC, a former super-premium cigarette and cigar business and General Manager for a joint venture, Richmark GmbH. Elizabeth Seegar serves as Vice President, Financial Planning & Analysis for Altrial Client Services ALCS. In her role, she oversees the development of financial models, financial forecasting, accounting and reporting and various analysis for Altria and its companies. Previously, Ms. Seegar served as Vice President, Corporate Audit for Altria, where she had oversight of both internal audit as well as Altria's Sarbanes-Oxley compliance program. Since 2003, Ms. Seegar has held a variety of leadership roles across Altria's Finance Department. 22#23wwwww APPENDIX#24(in thousands of U.S. dollars) Net loss Interest income, net Income tax expense (benefit) Depreciation and amortization EBITDA Share of (income) loss from equity method investments Impairment loss on long-lived assets Loss on revaluation of derivative liabilities(11) Loss on revaluation of financial instruments() Impairment loss on other investments (vii) Foreign currency transaction loss Other, net(iv) Restructuring costs (viii) Share-based compensation Financial statement review costs(vi) Inventory write-down(x) Adjusted EBITDA ADJUSTED EBITDA (NON-GAAP) RECONCILIATION For the year ended December 31, 2023 (in thousands of U.S. dollars) Three months ended December 31, 2023 Continuing Operations Discontinued Operations Total $ (70,439) $ (51,235) (4,114) $ (10) (74,553) Net loss со (51,245) Interest income, net (3,230) (3,230) Income tax expense (benefit) 7,866 244 8,110 (117,038) (3,880) (120,918) (1,583) 3,366 205 (1,583) 3,571 Depreciation and amortization EBITDA Share of (income) loss from equity method investments 1,177 (58,548) (752) Continuing Operations Discontinued Operations Total (45,151) $ 124 $ (45,027) (14,214) (1) (14,215) (360) (360) 1,177 123 Impairment loss on long-lived assets 3,366 85 85 12,042 12,042 23,350 23,350 7,324 7,324 Loss on revaluation of derivative liabilities() Loss on revaluation of financial instruments (vii) Impairment loss on other investments Foreign currency transaction loss 71 (III) 4,186 23,350 11,323 (1,114) 118 (996) Other, net(iv) (89) (14) 1,524 523 2,047 Restructuring costs (viii) 101 (39) 8,756 13 919 805 $ (61,564) S 839 (2,182) $ 8,769 919 1,644 (63.746) Share-based compensation Financial statement review costs() Inventory write-down(x) (V) 1,933 ||ཀླུ | | | | | | $ སྐྱིགློ (58,425) (752) 3,366 71 4,186 23,350 11,323 (103) 62 (4) 1,929 180 180 89 89 Adjusted EBITDA S (14.790) $ 66 $ (14,724) For the three months and year ended December 31, 2023, impairment loss on long-lived assets related to certain leased properties associated with the Company's former U.S. operations and impairment of the Company's CBCVA exclusive license under the collaboration and license agreement between Ginkgo and the Company. For the year ended December 31, 2022, impairment loss on long-lived assets related to the Company's decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. (i) For the three months and years ended December 31, 2023 and 2022, the (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. (i) For the three months and years ended December 31, 2023 and 2022, (gain) loss on revaluation of financial instruments relates primarily to our unrealized holding gain on our mark-to-market investment in Vitura as well as revaluations of financial liabilities resulting from deferred share units granted to directors. (iv) For the three months and years ended December 31, 2023 and 2022, other, net primarily related to related to (gain) loss on disposal of assets. For the three months and years ended December 31, 2023 and 2022, share-based compensation relates to the vesting expenses of share-based compensation awarded to employees under our share-based award plans. (vi) For the three months and years ended December 31, 2023 and 2022, financial statement review costs include costs related to the Restatements, costs related to the Company's responses to requests for information from various regulatory authorities relating to the Restatements, the costs related to the Settlement Order and Settlement Agreement and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement. (vii) For the three months ended December 31, 2023 and years ended December 31, 2023 and 2022, impairment loss on other investments related to the Pharma Cann Option for the difference between its fair value and carrying amount. (viii) For the three months and years ended December 31, 2023 and 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment. (x) For the three months and year ended December 31, 2023, inventory write-downs from discontinued operations relate to product destruction and obsolescence associated with the exit of our U.S. operations and inventory write- downs from continuing operations relate to product destruction and obsolescence associated with the planned exit of Cronos Fermentation. 24#25CRONOS GROUP THANK YOU NASDAQ / TSX TICKER CRON 25